ANTXAN2 Therapeutics, Inc.

Nasdaq an2therapeutics.com


$ 2.32 $ 0.04 (1.75 %)    

Friday, 26-Apr-2024 15:58:02 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 2.32
$ 2.22
$ 2.31 x 100
$ 0.00 x 0
$ 2.22 - $ 2.35
$ 2.20 - $ 22.22
121,380
na
54.75M
$ 1.64
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-29-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-29-2023 12-31-2022 10-K
6 11-09-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 05-10-2022 03-31-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jmp-securities-upgrades-an2-therapeutics-to-market-outperform-announces-6-price-target

JMP Securities analyst Roy Buchanan upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Market Outperform and ann...

 oppenheimer-reiterates-perform-on-an2-therapeuticsto-perform

Oppenheimer analyst Jeff Jones reiterates AN2 Therapeutics (NASDAQ:ANTX) from Perform to Perform.

 an2-therapeutics-q4-eps-057-beats-076-estimate

AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0....

 zoominfo-technologies-to-rally-around-50-here-are-10-top-analyst-forecasts-for-tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 leerink-partners-downgrades-an2-therapeutics-to-market-perform-lowers-price-target-to-7

Leerink Partners analyst Joseph Schwartz downgrades AN2 Therapeutics (NASDAQ:ANTX) from Outperform to Market Perform and low...

 nasdaq-edges-lower-contextlogic-shares-surge

U.S. stocks traded mostly higher toward the end of trading, while the Nasdaq Composite moved slightly lower on Monday. The Dow...

 why-big-lots-shares-are-trading-lower-by-around-31-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarte...

 evercore-isi-group-downgrades-an2-therapeutics-to-in-line-lowers-price-target-to-7

Evercore ISI Group analyst Liisa Bayko downgrades AN2 Therapeutics (NASDAQ:ANTX) from Outperform to In-Line and lowers the p...

 dow-surges-over-150-points-gilead-sciences-to-acquire-cymabay-therapeutics-for-43b

U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded u...

 oppenheimer-downgrades-an2-therapeutics-to-perform

Oppenheimer analyst Jeff Jones downgrades AN2 Therapeutics (NASDAQ:ANTX) from Outperform to Perform.

 jmp-securities-downgrades-an2-therapeutics-to-market-perform

JMP Securities analyst Roy Buchanan downgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Outperform to Market Perform.

 us-stocks-mixed-trimble-issues-weak-outlook

U.S. stocks traded mixed this morning, with the Dow Jones index falling around 20 points on Monday. Following the market openi...

 why-is-infectious-disease-focused-an2-therapeutics-stock-sinking-today

AN2 Therapeutics pauses Phase 3 enrollment for epetraborole trial in Mycobacterium Avium Complex lung disease. Updates expected...

 mondaycom-reports-q4-results-joins-an2-therapeuticsand-other-big-stocks-moving-lower-in-mondays-pre-market-session

U.S. stock futures were mixed this morning, with the Dow futures trading lower by around 45 points on Monday. Shares of monda...

 an2-therapeutics-to-voluntarily-pause-enrollment-in-phase-3-part-of-phase-23-pivotal-clinical-trial-evaluating-epetraborole-for-treatment-refractory-mycobacterium-avium-complex-mac-lung-disease

AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chr...

 jmp-securities-initiates-coverage-on-an2-therapeutics-with-market-outperform-rating-announces-price-target-of-30

JMP Securities analyst Roy Buchanan initiates coverage on AN2 Therapeutics (NASDAQ:ANTX) with a Market Outperform rating and...

 an2-therapeutics-q3-eps-065-beats-070-estimate

AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0....

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION